Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.78 +3.7%	$0.77	$0.54 ▼ $1.99	$59.94M	1.55	242,673 shs	235,359 shs
INMB INmune Bio	$2.04 +3.8%	$2.20	$1.71 ▼ $11.64	$53.69M	1.04	1.40 million shs	106,884 shs
IXHL Incannex Healthcare	$0.45 +1.7%	$0.53	$0.08 ▼ $3.12	$154.73M	7.5	62.18 million shs	14.27 million shs
KPTI Karyopharm Therapeutics	$5.01 -13.2%	$5.89	$3.51 ▼ $16.95	$43.44M	0.34	133,399 shs	2.25 million shs

These 7 Stocks Will Be Magnificent in 2025

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+3.42%	+4.69%	-3.54%	-3.94%	-45.68%
INMB INmune Bio	-4.85%	-5.31%	+0.51%	-16.95%	-62.60%
IXHL Incannex Healthcare	-1.57%	-5.75%	-16.65%	+98.10%	-72.30%
KPTI Karyopharm Therapeutics	-6.33%	-11.77%	-12.58%	+19.96%	-55.79%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CUE Cue Biopharma	$0.78 +3.7%	$0.77	$0.54 ▼ $1.99	$59.94M	1.55	242,673 shs	235,359 shs
INMB INmune Bio	$2.04 +3.8%	$2.20	$1.71 ▼ $11.64	$53.69M	1.04	1.40 million shs	106,884 shs
IXHL Incannex Healthcare	$0.45 +1.7%	$0.53	$0.08 ▼ $3.12	$154.73M	7.5	62.18 million shs	14.27 million shs
KPTI Karyopharm Therapeutics	$5.01 -13.2%	$5.89	$3.51 ▼ $16.95	$43.44M	0.34	133,399 shs	2.25 million shs

These 7 Stocks Will Be Magnificent in 2025

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CUE Cue Biopharma	+3.42%	+4.69%	-3.54%	-3.94%	-45.68%
INMB INmune Bio	-4.85%	-5.31%	+0.51%	-16.95%	-62.60%
IXHL Incannex Healthcare	-1.57%	-5.75%	-16.65%	+98.10%	-72.30%
KPTI Karyopharm Therapeutics	-6.33%	-11.77%	-12.58%	+19.96%	-55.79%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CUE Cue Biopharma	1.00	Sell	N/A	N/A
INMB INmune Bio	2.38	Hold	$18.50	809.09% Upside
IXHL Incannex Healthcare	1.00	Sell	N/A	N/A
KPTI Karyopharm Therapeutics	2.50	Moderate Buy	$34.00	578.64% Upside

Current Analyst Ratings Breakdown

Latest IXHL, CUE, KPTI, and INMB Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/8/2025	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
10/8/2025	IXHL Incannex Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
10/8/2025	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	CUE Cue Biopharma	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	INMB INmune Bio	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	IXHL Incannex Healthcare	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
9/27/2025	KPTI Karyopharm Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/12/2025	KPTI Karyopharm Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$42.00 ➝ $25.00
7/16/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Buy ➝ Neutral
7/11/2025	KPTI Karyopharm Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$27.00

(Data available from 10/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CUE Cue Biopharma	$9.29M	6.45	N/A	N/A	$0.28 per share	2.79
INMB INmune Bio	$10K	5,409.03	N/A	N/A	$1.45 per share	1.40
IXHL Incannex Healthcare	$90K	1,719.23	N/A	N/A	$0.07 per share	6.36
KPTI Karyopharm Therapeutics	$145.24M	0.30	N/A	N/A	($22.10) per share	-0.23

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CUE Cue Biopharma	-$40.67M	-$0.56	N/A	N/A	N/A	-469.35%	-230.13%	-111.16%	11/13/2025 (Estimated)
INMB INmune Bio	-$42.08M	-$2.48	N/A	N/A	N/A	N/A	-120.62%	-92.94%	10/30/2025 (Estimated)
IXHL Incannex Healthcare	-$46.88M	-$1.21	N/A	∞	N/A	N/A	-671.36%	-298.35%	N/A
KPTI Karyopharm Therapeutics	-$76.42M	-$14.59	N/A	N/A	N/A	-90.02%	N/A	-84.28%	11/4/2025 (Estimated)

Latest IXHL, CUE, KPTI, and INMB Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/4/2025	Q3 2025	KPTI Karyopharm Therapeutics	-$3.67	N/A	N/A	N/A	$39.56 million	N/A
10/30/2025	Q3 2025	INMB INmune Bio	-$0.31	N/A	N/A	N/A	N/A	N/A
8/12/2025	Q2 2025	CUE Cue Biopharma	-$0.13	-$0.09	+$0.04	-$0.09	$2.00 million	$2.95 million
8/11/2025	Q2 2025	KPTI Karyopharm Therapeutics	-$3.80	-$4.32	-$0.52	-$4.32	$37.92 million	$37.93 million
8/7/2025	Q2 2025	INMB INmune Bio	-$0.37	-$0.34	+$0.03	-$1.05	$0.00 million	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CUE Cue Biopharma	N/A	N/A	N/A	N/A	N/A
INMB INmune Bio	N/A	N/A	N/A	N/A	N/A
IXHL Incannex Healthcare	N/A	N/A	N/A	N/A	N/A
KPTI Karyopharm Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CUE Cue Biopharma	0.01	1.60	1.60
INMB INmune Bio	N/A	4.20	4.20
IXHL Incannex Healthcare	N/A	2.86	2.86
KPTI Karyopharm Therapeutics	N/A	0.99	0.94

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CUE Cue Biopharma	35.04%
INMB INmune Bio	12.72%
IXHL Incannex Healthcare	0.43%
KPTI Karyopharm Therapeutics	66.44%

Insider Ownership

Company	Insider Ownership
CUE Cue Biopharma	12.26%
INMB INmune Bio	35.70%
IXHL Incannex Healthcare	15.49%
KPTI Karyopharm Therapeutics	2.75%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CUE Cue Biopharma	60	76.85 million	67.43 million	Optionable
INMB INmune Bio	10	26.58 million	17.09 million	Optionable
IXHL Incannex Healthcare	3	347.71 million	293.85 million	Not Optionable
KPTI Karyopharm Therapeutics	380	8.67 million	8.43 million	Optionable

IXHL, CUE, KPTI, and INMB Headlines

Recent News About These Companies

Karyopharm rises on securing $100M in financing to extend cash runway into Q2 2026

2 hours ago | msn.com

Karyopharm shares slide after unveiling $100 million financing package

2 hours ago | msn.com

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY ...

2 hours ago | finance.yahoo.com

Karyopharm Announces Strategic Financing Transactions to Support Growth; Extends Cash Runway Into Second Quarter of 2026, Beyond Expected Top-Line Readout of Phase 3 SENTRY Trial in Myelofibrosis

October 8 at 7:00 AM | prnewswire.com

Karyopharm Therapeutics (NASDAQ:KPTI) Share Price Passes Above 50-Day Moving Average - Here's Why

October 7 at 6:27 AM | marketbeat.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 1, 2025 | prnewswire.com

Goldman Sachs Group Inc. Sells 1,250,361 Shares of Karyopharm Therapeutics Inc. $KPTI

September 28, 2025 | marketbeat.com

Karyopharm Therapeutics (KPTI) Moves 27.9% Higher: Will This Strength Last?

September 24, 2025 | zacks.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Given Average Recommendation of "Moderate Buy" by Analysts

September 16, 2025 | marketbeat.com

Karyopharm Therapeutics Inc.: Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

September 10, 2025 | finanznachrichten.de

Karyopharm completes enrollment in Phase 3 Sentry trial

September 10, 2025 | msn.com

Karyopharm Announces Completion of Enrollment in the Phase 3 SENTRY Trial in Myelofibrosis

September 10, 2025 | prnewswire.com

Adage Capital Partners GP L.L.C. Lowers Stake in Karyopharm Therapeutics Inc. $KPTI

September 10, 2025 | marketbeat.com

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

September 2, 2025 | prnewswire.com

Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Q2 2025 Earnings Call Transcript

August 13, 2025 | msn.com

Karyopharm’s Earnings Call: Clinical Wins Amid Financial Strain

August 13, 2025 | msn.com

Karyopharm Therapeutics Inc.: Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

August 12, 2025 | finanznachrichten.de

Karyopharm Therapeutics: Q2 Earnings Snapshot

August 12, 2025 | chron.com

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Lags Revenue Estimates

August 11, 2025 | zacks.com

Karyopharm Therapeutics Inc. (KPTI) Q2 2025 Earnings Call Transcript

August 11, 2025 | seekingalpha.com

Karyopharm Reports Second Quarter 2025 Financial Results and Highlights Recent Company Progress

August 11, 2025 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, CUE, KPTI, and INMB Company Descriptions

Cue Biopharma NASDAQ:CUE

$0.78 +0.03 (+3.67%)

As of 01:17 PM Eastern

Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops a novel class of injectable therapeutics to selectively engage and modulate targeted, disease relevant T cells directly within the patient's body. Its lead drug product candidate is CUE-101 for the treatment of human papilloma virus (HPV16+)-driven recurrent/metastatic head and neck cancer. The company is also developing CUE-102 targets Wilms' Tumor 1 protein in various cancers; CUE-103, a CUE-100 series drug product candidate; and Neo-STAT and RDI-STAT programs outside of oncology, including CUE-200, CUE-300, and CUE-400 series. It has collaboration agreements with LG Chem, Ltd. for the development of Immuno-STATs focused in the field of oncology; strategic collaboration and option agreement with Ono Pharmaceutical Co., Ltd. to advance CUE-401 for the treatment of autoimmune and inflammatory diseases; and license agreement with Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Boston, Massachusetts.

INmune Bio NASDAQ:INMB

$2.04 +0.08 (+3.83%)

As of 01:18 PM Eastern

INmune Bio, Inc., a clinical-stage immunology company, focuses on developing drugs to reprogram the patients innate immune system to treat disease in the United States. It intends to develop and commercialize product candidates to treat hematologic malignancies, solid tumors, and chronic inflammation. The company's development programs include INKmune, which is in Phase 1 for the treatment of patients with high-risk myelodysplastic syndrome; and INB03, a mucinous polyglucan on the surface of some epithelial cancer cells that appears to predict resistant to immunotherapy, including women with MUC4 expressing HER2+ breast cancer and other MUC4 resistant cancers. It also provides XPro1595 for the treatment of Alzheimer's disease and treatment resistant depression. It has license agreements with Xencor, Inc.; Immune Ventures, LLC; and University of Pittsburg. INmune Bio, Inc. was incorporated in 2015 and is headquartered in Boca Raton, Florida.

Incannex Healthcare NASDAQ:IXHL

$0.44 +0.01 (+1.69%)

As of 01:19 PM Eastern

Incannex Healthcare Inc., a clinical stage pharmaceutical development company, engages in the research, development, and sale of medicinal cannabinoid and psychedelic pharmaceutical products and therapies. It develops products for the treatment of obstructive sleep apnoea (OSA), traumatic brain injury (TBI) and concussion, lung inflammation (ARDS, COPD, asthma, bronchitis), rheumatoid arthritis, inflammatory bowel disease, anxiety disorders, addiction disorders, pain, and other indications. The company offers APIRx-1801, an ultrapure tetrahydrocannabinol; APIRx-1802, an ultrapure CBD; and APIRx-1803, an ultrapure cannabigerol. It also develops IHL-42X, which has completed Phase IIb clinical trial for obstructive sleep apnea; Psi-GAD that is in Phase IIa clinical trial for generalized anxiety disorder; MedChew Dronabinol, which has completed Phase Ia clinical trial for nausea and vomiting in chemotherapy; CanChew Plus that has completed Phase IIa clinical trial for irritable bowel syndrome; APIRx-1601, which has completed Phase IIa clinical trial for vitiligo; APIRx-1602 skin that has completed Phase IIa clinical trial for psoriasis; and APIRx-1603, which has completed Phase IIa clinical trial for atopic dermatitis. In addition, its product portfolio includes IHL-675A for inflammatory lung disease, IHL-675A for rheumatoid arthritis, IHL-675A for inflammatory bowel disease, and IHL-216A for traumatic brain injury and concussion, which have completed pre-clinical trials; and MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpatic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for chrohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for addiction of cannabis, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, suppoCan gastro for IBD, and APIRx-1702 for dry eye syndrome that are in pre-clinical trials. Incannex Healthcare Inc. was incorporated in 2001 and is based in Sydney, Australia.

Karyopharm Therapeutics NASDAQ:KPTI

$5.01 -0.76 (-13.17%)

As of 01:18 PM Eastern

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compound, include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also developing Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating Myelodysplastic Neoplasms, as well as verdinexor, KPT-9274, and IL-12 compounds. The company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, it has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed/refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IXHL, CUE, KPTI, and INMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IXHL, CUE, KPTI, and INMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IXHL, CUE, KPTI, and INMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, CUE, KPTI, and INMB Company Descriptions

Cue Biopharma NASDAQ:CUE

INmune Bio NASDAQ:INMB

Incannex Healthcare NASDAQ:IXHL

Karyopharm Therapeutics NASDAQ:KPTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest IXHL, CUE, KPTI, and INMB Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest IXHL, CUE, KPTI, and INMB Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

IXHL, CUE, KPTI, and INMB Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

IXHL, CUE, KPTI, and INMB Company Descriptions

Cue Biopharma NASDAQ:CUE

INmune Bio NASDAQ:INMB

Incannex Healthcare NASDAQ:IXHL

Karyopharm Therapeutics NASDAQ:KPTI

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools